We are live on ! Find out more
TECX

Tectonic Therapeutic

70 hedge funds and large institutions have $355M invested in Tectonic Therapeutic in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

63% more capital invested

Capital invested by funds: $217M → $355M (+$137M)

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

32% more funds holding

Funds holding: 5370 (+17)

3.4% more ownership

Funds ownership: 48.72%52.11% (+3.4%)

60% less funds holding in top 10

Funds holding in top 10: 52 (-3)

Holders
70
Holders Change
+17
Holders Change %
+32.08%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
25
Increased
21
Reduced
15
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$70M +$12.5M +296,197 +24%
VVA
2
Vida Ventures Advisors
Massachusetts
$47.5M
EC
3
EcoR1 Capital
California
$39.2M
FCM
4
Farallon Capital Management
California
$32.9M +$8.15M +192,653 +37%
5VM
5
5AM Venture Management
California
$27.5M -$2.11M -49,864 -8%
PBA
6
Paradigm Biocapital Advisors
New York
$22.4M +$20.5M +485,105 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$16.7M -$3.46M -81,766 -18%
Balyasny Asset Management
8
Balyasny Asset Management
Illinois
$11.4M +$2.81M +66,527 +37%
BlackRock
9
BlackRock
New York
$9.01M +$3.05M +72,027 +59%
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$7.69M +$4.39M +103,698 +165%
IC
11
Ikarian Capital
Texas
$6.57M -$5.28M -124,817 -47%
WP
12
Woodline Partners
California
$6.01M +$2.73M +64,661 +99%
Invesco
13
Invesco
Georgia
$5.92M +$5.42M +128,178 New
TCM
14
Tang Capital Management
California
$3.66M
AVLSA
15
Atlas Venture Life Science Advisors
Massachusetts
$3.62M -$12.7M -300,000 -79%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$3.58M +$29.8K +705 +0.9%
Walleye Capital
17
Walleye Capital
New York
$3.39M +$23.5K +555 +0.8%
ACM
18
ADAR1 Capital Management
Texas
$2.71M -$2.89M -68,451 -54%
AAA
19
Affinity Asset Advisors
New York
$2.69M
Renaissance Technologies
20
Renaissance Technologies
New York
$2.22M -$369K -8,724 -15%
BFM
21
Boothbay Fund Management
New York
$1.91M -$1.45M -34,337 -45%
AC
22
Aldebaran Capital
Indiana
$1.9M -$33.2K -784 -2%
ACP
23
Acuta Capital Partners
California
$1.52M +$817K +19,308 +141%
SCM
24
Soleus Capital Management
Connecticut
$1.47M +$1.35M +31,841 New
Qube Research & Technologies (QRT)
25
Qube Research & Technologies (QRT)
United Kingdom
$1.37M +$1.26M +29,757 New

TECX Hedge Fund Activity: Q4 2024 in Review

70 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Tectonic Therapeutic (TECX) for Q4 2024, worth a combined $355M — up 63% from $217M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TECX positions and 8 closed out — a net gain of 17 holders — while 21 added to existing stakes and 15 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $20.5M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $12.7M.

  • 70 institutional investors held Tectonic Therapeutic (TECX) as of Q4 2024, up from 53 in Q3 2024.
  • Funds reported $355M of Tectonic Therapeutic stock for Q4 2024, up 63% quarter-over-quarter.
  • 25 funds opened new Tectonic Therapeutic positions in Q4 2024 and 8 closed out, a net change of +17 holders.
  • The largest Tectonic Therapeutic buyer in Q4 2024 was Paradigm Biocapital Advisors, an estimated $20.5M added.
  • The largest Tectonic Therapeutic seller in Q4 2024 was Atlas Venture Life Science Advisors, an estimated $12.7M sold.

Based on aggregated 13F filings for Q4 2024.